Apr 22, 2024 | Press Releases
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) — Phio...
Apr 16, 2024 | Press Releases
Phio’s lead clinical product candidate, PH-762, is the subject of three new dermatological postersMARLBOROUGH, Mass., April 16, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary...
Apr 11, 2024 | Press Releases
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing...
Apr 3, 2024 | Press Releases
-Program will be airing on PBS with Dennis Quaid in April -It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary...
Apr 2, 2024 | Press Releases
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatments, extending Phio’s expertise in dermatological...